Drug Profile
Levodopa - Acorda Therapeutics
Alternative Names: CVT-301; INBRIJALatest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Civitas Therapeutics
- Developer Acorda Therapeutics
- Class Antiasthmatics; Antiparkinsonians; Catecholamines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Parkinson's disease
- No development reported Asthma; Smoking withdrawal
Most Recent Events
- 02 Apr 2024 Merz Pharmaceuticals enters into an asset purchase agreement with Acorda Therapeutics to acquire Inbrija and Amprya
- 06 Nov 2023 Preregistration for Parkinson's disease in Argentina, Colombia, Costa Rica, Ecuador, Panama, Peru (Inhalation)
- 06 Nov 2023 Acorda Therapeutics announces intention to get approval for Levodopa in upto 5 American countries in 2024